$LH Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in LABORATORY CORP OF AMERICA HOLDINGS.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in LABORATORY CORP OF AMERICA HOLDINGS. Get notifications about new insider transactions in LABORATORY CORP OF AMERICA HOLDINGS for free.
Page: < prev 1 2 3 4 5 6 ... 37 next >
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 04 2021 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Option Exercise | A | 0.00 | 771 | 0 | 1,757 | |
Feb 04 2021 | LH | LABORATORY CORP OF ... | Parham Richelle P | Director | Option Exercise | A | 0.00 | 771 | 0 | 1,757 | |
Feb 04 2021 | LH | LABORATORY CORP OF ... | NEUPERT PETER M | Director | Option Exercise | A | 0.00 | 771 | 0 | 1,757 | |
Feb 04 2021 | LH | LABORATORY CORP OF ... | Gilliland Dwight Gary | Director | Option Exercise | A | 0.00 | 771 | 0 | 1,757 | |
Feb 04 2021 | LH | LABORATORY CORP OF ... | Davis Jeffrey A. | Director | Option Exercise | A | 0.00 | 771 | 0 | 1,757 | |
Feb 04 2021 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Option Exercise | A | 0.00 | 771 | 0 | 1,757 | |
Feb 04 2021 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Option Exercise | A | 0.00 | 771 | 0 | 1,757 | |
Feb 04 2021 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Gift | G | 0.00 | 746 | 0 | 18,894 | 19.6 K to 18.9 K (-3.80 %) |
Jan 28 2021 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Option Exercise | M | 98.49 | 1,300 | 128,037 | 0 | |
Jan 28 2021 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Buy | M | 98.49 | 1,300 | 128,037 | 5,246 | 3.9 K to 5.2 K (+32.94 %) |
Jan 28 2021 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Gift | G | 0.00 | 1,149 | 0 | 3,946 | 5.1 K to 3.9 K (-22.55 %) |
Dec 14 2020 | LH | LABORATORY CORP OF ... | Davis Jeffrey A. | Director | Option Exercise | M | 0.00 | 173 | 0 | 986 | |
Dec 14 2020 | LH | LABORATORY CORP OF ... | Davis Jeffrey A. | Director | Buy | M | 0.00 | 173 | 0 | 173 | 0 to 173 |
Nov 09 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 2,010 | 0 | 6,501 | |
Nov 09 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 214.42 | 835 | 179,041 | 4,537 | 5.4 K to 4.5 K (-15.54 %) |
Nov 09 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 2,010 | 0 | 5,372 | 3.4 K to 5.4 K (+59.79 %) |
Nov 06 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Sell | S | 214.14 | 1,500 | 321,204 | 7,698 | 9.2 K to 7.7 K (-16.31 %) |
Nov 04 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 2,006 | 0 | 7,602 | |
Nov 04 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 207.23 | 895 | 185,471 | 9,198 | 10.1 K to 9.2 K (-8.87 %) |
Nov 04 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 2,006 | 0 | 9,198 | 7.2 K to 9.2 K (+27.89 %) |
Sep 29 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 970 | 0 | 13,218 | |
Sep 29 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 180.99 | 289 | 52,306 | 3,097 | 3.4 K to 3.1 K (-8.54 %) |
Sep 29 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 970 | 0 | 3,386 | 2.4 K to 3.4 K (+40.15 %) |
Aug 18 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | A | 0.00 | 150 | 0 | 2,334 | |
Jul 10 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Option Exercise | M | 98.49 | 1,300 | 128,037 | 1,300 | |
Jul 10 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Sell | S | 173.12 | 1,300 | 225,056 | 5,095 | 6.4 K to 5.1 K (-20.33 %) |
Jul 10 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Buy | M | 98.49 | 1,300 | 128,037 | 6,395 | 5.1 K to 6.4 K (+25.52 %) |
Jul 07 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Sell | S | 170.00 | 435 | 73,950 | 4,044 | 4.5 K to 4 K (-9.71 %) |
Jun 26 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Sell | S | 160.33 | 436 | 69,904 | 4,479 | 4.9 K to 4.5 K (-8.87 %) |
Jun 26 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Sell | S | 160.33 | 436 | 69,904 | 4,915 | 5.4 K to 4.9 K (-8.15 %) |
May 07 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Sell | S | 160.00 | 31,250 | 5,000,000 | 312,554 | 343.8 K to 312.6 K (-9.09 %) |
May 04 2020 | LH | LABORATORY CORP OF ... | Seltz Judith C | EVP, CHRO | Buy | P | 168.56 | 330 | 55,625 | 580 | 250 to 580 (+132.00 %) |
May 04 2020 | LH | LABORATORY CORP OF ... | Seltz Judith C | EVP, CHRO | Buy | P | 174.94 | 250 | 43,735 | 250 | 0 to 250 |
Apr 07 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 1,010 | 0 | 9,608 | |
Apr 07 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 113.31 | 372 | 42,151 | 8,087 | 8.5 K to 8.1 K (-4.40 %) |
Apr 07 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 1,010 | 0 | 8,459 | 7.4 K to 8.5 K (+13.56 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 131.95 | 24,583 | 3,243,727 | 343,804 | 368.4 K to 343.8 K (-6.67 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 131.95 | 24,583 | 3,243,727 | 343,804 | 368.4 K to 343.8 K (-6.67 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Grant | A | 0.00 | 54,995 | 0 | 368,387 | 313.4 K to 368.4 K (+17.55 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Grant | A | 0.00 | 54,995 | 0 | 368,387 | 313.4 K to 368.4 K (+17.55 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Payment of Exercise | F | 131.95 | 1,106 | 145,937 | 5,351 | 6.5 K to 5.4 K (-17.13 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | EVP, Chief Legal Of ... | Grant | A | 0.00 | 3,721 | 0 | 6,457 | 2.7 K to 6.5 K (+136.00 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 131.95 | 5,787 | 763,595 | 26,124 | 31.9 K to 26.1 K (-18.13 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Grant | A | 0.00 | 12,945 | 0 | 31,911 | 19 K to 31.9 K (+68.25 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 131.95 | 1,014 | 133,797 | 7,449 | 8.5 K to 7.4 K (-11.98 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Grant | A | 0.00 | 3,402 | 0 | 8,463 | 5.1 K to 8.5 K (+67.22 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 131.95 | 1,153 | 152,138 | 3,213 | 4.4 K to 3.2 K (-26.41 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Grant | A | 0.00 | 3,880 | 0 | 4,366 | 486 to 4.4 K (+798.35 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Payment of Exercise | F | 131.95 | 1,695 | 223,655 | 10,543 | 12.2 K to 10.5 K (-13.85 %) |
Apr 01 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | EVP, CIO & CTO | Grant | A | 0.00 | 3,880 | 0 | 12,238 | 8.4 K to 12.2 K (+46.42 %) |
Feb 25 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Sell | S | 189.65 | 297 | 56,326 | 297 | 594 to 297 (-50.00 %) |
Feb 21 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Option Exercise | M | 77.19 | 3,100 | 239,289 | 0 | |
Feb 21 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Sell | S | 189.76 | 26,479 | 5,024,750 | 14,682 | 41.2 K to 14.7 K (-64.33 %) |
Feb 21 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Buy | M | 77.19 | 3,100 | 239,289 | 41,161 | 38.1 K to 41.2 K (+8.14 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | M | 0.00 | 940 | 0 | 35,650 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | M | 0.00 | 780 | 0 | 36,590 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 187.51 | 280 | 52,503 | 18,966 | 19.2 K to 19 K (-1.45 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Buy | M | 0.00 | 940 | 0 | 19,246 | 18.3 K to 19.2 K (+5.13 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 187.51 | 232 | 43,502 | 18,306 | 18.5 K to 18.3 K (-1.25 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Buy | M | 0.00 | 780 | 0 | 18,538 | 17.8 K to 18.5 K (+4.39 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 283 | 0 | 8,511 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 233 | 0 | 8,794 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 188.49 | 103 | 19,414 | 486 | 589 to 486 (-17.49 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 188.49 | 85 | 16,022 | 589 | 674 to 589 (-12.61 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 187.51 | 78 | 14,626 | 674 | 752 to 674 (-10.37 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 283 | 0 | 752 | 469 to 752 (+60.34 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 187.51 | 64 | 12,001 | 469 | 533 to 469 (-12.01 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 233 | 0 | 533 | 300 to 533 (+77.67 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | M | 0.00 | 353 | 0 | 6,768 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | M | 0.00 | 2,353 | 0 | 7,121 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | M | 0.00 | 233 | 0 | 9,474 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Payment of Exercise | F | 187.51 | 105 | 19,689 | 8,358 | 8.5 K to 8.4 K (-1.24 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Buy | M | 0.00 | 353 | 0 | 8,463 | 8.1 K to 8.5 K (+4.35 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Payment of Exercise | F | 187.51 | 699 | 131,069 | 8,110 | 8.8 K to 8.1 K (-7.94 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Buy | M | 0.00 | 2,353 | 0 | 8,809 | 6.5 K to 8.8 K (+36.45 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Payment of Exercise | F | 187.51 | 68 | 12,751 | 6,456 | 6.5 K to 6.5 K (-1.04 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Buy | M | 0.00 | 233 | 0 | 6,524 | 6.3 K to 6.5 K (+3.70 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 2,353 | 0 | 14,188 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 283 | 0 | 16,541 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Option Exercise | M | 0.00 | 233 | 0 | 16,824 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 187.51 | 698 | 130,882 | 2,326 | 3 K to 2.3 K (-23.08 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 2,353 | 0 | 3,024 | 671 to 3 K (+350.67 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 187.51 | 86 | 16,126 | 671 | 757 to 671 (-11.36 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 283 | 0 | 757 | 474 to 757 (+59.70 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Payment of Exercise | F | 187.51 | 82 | 15,376 | 474 | 556 to 474 (-14.75 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Caveney Brian J | EVP, President of D ... | Buy | M | 0.00 | 233 | 0 | 556 | 323 to 556 (+72.14 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | M | 0.00 | 680 | 0 | 2,184 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Option Exercise | M | 0.00 | 186 | 0 | 2,864 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Payment of Exercise | F | 187.51 | 206 | 38,627 | 594 | 800 to 594 (-25.75 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Buy | M | 0.00 | 680 | 0 | 800 | 120 to 800 (+566.67 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Payment of Exercise | F | 187.51 | 66 | 12,376 | 120 | 186 to 120 (-35.48 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Wilkinson Peter J | SVP, Chief Accounti ... | Buy | M | 0.00 | 186 | 0 | 186 | 0 to 186 |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 316 | 0 | 10,618 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 263 | 0 | 10,934 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 187.51 | 88 | 16,501 | 5,061 | 5.1 K to 5.1 K (-1.71 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 316 | 0 | 5,149 | 4.8 K to 5.1 K (+6.54 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 187.51 | 71 | 13,313 | 4,833 | 4.9 K to 4.8 K (-1.45 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 263 | 0 | 4,904 | 4.6 K to 4.9 K (+5.67 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Option Exercise | M | 0.00 | 4,236 | 0 | 50,558 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Option Exercise | M | 0.00 | 3,513 | 0 | 54,794 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 187.51 | 1,894 | 355,144 | 313,392 | 315.3 K to 313.4 K (-0.60 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Buy | M | 0.00 | 4,236 | 0 | 315,286 | 311.1 K to 315.3 K (+1.36 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 187.51 | 1,386 | 259,889 | 311,050 | 312.4 K to 311.1 K (-0.44 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Buy | M | 0.00 | 3,513 | 0 | 312,436 | 308.9 K to 312.4 K (+1.14 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Buy | M | 0.00 | 1,227 | 0 | 19,160 | 17.9 K to 19.2 K (+6.84 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Payment of Exercise | F | 187.51 | 123 | 23,064 | 38,061 | 38.2 K to 38.1 K (-0.32 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Buy | M | 0.00 | 1,227 | 0 | 38,184 | 37 K to 38.2 K (+3.32 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Gilliland Dwight Gary | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Gilliland Dwight Gary | Director | Buy | M | 0.00 | 1,227 | 0 | 5,766 | 4.5 K to 5.8 K (+27.03 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Buy | M | 0.00 | 1,227 | 0 | 8,452 | 7.2 K to 8.5 K (+16.98 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | NEUPERT PETER M | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | NEUPERT PETER M | Director | Buy | M | 0.00 | 1,227 | 0 | 9,996 | 8.8 K to 10 K (+13.99 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Parham Richelle P | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Parham Richelle P | Director | Buy | M | 0.00 | 1,227 | 0 | 5,088 | 3.9 K to 5.1 K (+31.78 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Option Exercise | M | 0.00 | 1,227 | 0 | 986 | |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Sell | S | 188.49 | 1,227 | 231,277 | 5,095 | 6.3 K to 5.1 K (-19.41 %) |
Feb 14 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Buy | M | 0.00 | 1,227 | 0 | 6,322 | 5.1 K to 6.3 K (+24.08 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Option Exercise | M | 0.00 | 297 | 0 | 9,027 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Sell | S | 181.99 | 108 | 19,655 | 300 | 408 to 300 (-26.47 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Payment of Exercise | F | 182.33 | 82 | 14,951 | 408 | 490 to 408 (-16.73 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Schroeder Mark S | EVP, President-Diag ... | Buy | M | 0.00 | 297 | 0 | 490 | 193 to 490 (+153.89 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Option Exercise | M | 0.00 | 367 | 0 | 2,330 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Sell | S | 181.99 | 133 | 24,205 | 2,529 | 2.7 K to 2.5 K (-5.00 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Payment of Exercise | F | 182.33 | 101 | 18,415 | 2,662 | 2.8 K to 2.7 K (-3.66 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | van der Vaart Sandra D | SVP, Global General ... | Buy | M | 0.00 | 367 | 0 | 2,763 | 2.4 K to 2.8 K (+15.32 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Option Exercise | M | 0.00 | 337 | 0 | 11,197 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Payment of Exercise | F | 182.33 | 103 | 18,780 | 4,641 | 4.7 K to 4.6 K (-2.17 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | Kirchgraber Paul R | CEO, Covance Drug D ... | Buy | M | 0.00 | 337 | 0 | 4,744 | 4.4 K to 4.7 K (+7.65 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Option Exercise | M | 0.00 | 4,220 | 0 | 58,307 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Payment of Exercise | F | 182.33 | 1,252 | 228,277 | 308,923 | 310.2 K to 308.9 K (-0.40 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | KING DAVID P | Director | Buy | M | 0.00 | 4,220 | 0 | 310,175 | 306 K to 310.2 K (+1.38 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Option Exercise | M | 0.00 | 994 | 0 | 37,370 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Payment of Exercise | F | 182.33 | 295 | 53,787 | 17,758 | 18.1 K to 17.8 K (-1.63 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | EISENBERG GLENN A | Chief Financial Off ... | Buy | M | 0.00 | 994 | 0 | 18,053 | 17.1 K to 18.1 K (+5.83 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Option Exercise | M | 0.00 | 297 | 0 | 9,707 | |
Feb 11 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Payment of Exercise | F | 182.33 | 103 | 18,780 | 6,291 | 6.4 K to 6.3 K (-1.61 %) |
Feb 11 2020 | LH | LABORATORY CORP OF ... | BERBERIAN LANCE | SVP, Chief Informat ... | Buy | M | 0.00 | 297 | 0 | 6,394 | 6.1 K to 6.4 K (+4.87 %) |
Feb 07 2020 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 07 2020 | LH | LABORATORY CORP OF ... | Kong Garheng | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Williams R Sanders | Director | Gift | G | 0.00 | 1,791 | 0 | 5,095 | 6.9 K to 5.1 K (-26.01 %) |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Parham Richelle P | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | NEUPERT PETER M | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Gilliland Dwight Gary | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | Davis Jeffrey A. | Director | Option Exercise | A | 0.00 | 986 | 0 | 1,159 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | BELINGARD JEAN-LUC | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 | |
Feb 06 2020 | LH | LABORATORY CORP OF ... | ANDERSON KERRII B | Director | Option Exercise | A | 0.00 | 986 | 0 | 2,213 |